{"id":"enoxaparine-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Elevated transaminases"}]},"_chembl":{"chemblId":"CHEMBL1201685","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. The low-molecular-weight formulation provides more predictable pharmacokinetics and predominantly anti-Xa activity compared to unfractionated heparin.","oneSentence":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:56.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prophylaxis in surgical patients"},{"name":"Treatment of deep vein thrombosis and pulmonary embolism"},{"name":"Acute coronary syndrome"},{"name":"Prevention of thromboembolic complications in atrial fibrillation"}]},"trialDetails":[{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT06180889","phase":"PHASE2","title":"Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2023-12-20","conditions":"Knee Arthroplasty, Total","enrollment":241},{"nctId":"NCT05618808","phase":"PHASE2","title":"A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-05-24","conditions":"Venous Thromboembolism","enrollment":373},{"nctId":"NCT04997265","phase":"NA","title":"Strategies for Anticoagulation During Venovenous ECMO","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-05-12","conditions":"Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism","enrollment":26},{"nctId":"NCT06868823","phase":"","title":"Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","status":"RECRUITING","sponsor":"University Hospital, Motol","startDate":"2025-05-01","conditions":"Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT05794165","phase":"PHASE2","title":"Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism","status":"ENROLLING_BY_INVITATION","sponsor":"Bryan Cotton","startDate":"2023-09-27","conditions":"Trauma Injury, Thromboembolism, Venous Thromboembolism","enrollment":314},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT04367831","phase":"PHASE4","title":"Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-05-02","conditions":"COVID-19, Venous Thromboses, Arterial Thrombosis","enrollment":94},{"nctId":"NCT06442267","phase":"PHASE4","title":"Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-07-30","conditions":"Respiratory Insufficiency, Circulatory Failure, Thromboembolism","enrollment":90},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT06293287","phase":"PHASE2","title":"Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy","status":"UNKNOWN","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2024-01-31","conditions":"Radial Artery Occlusion","enrollment":156},{"nctId":"NCT02604238","phase":"PHASE3","title":"Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism","status":"WITHDRAWN","sponsor":"Azienda U.S.L. 1 di Massa e Carrara","startDate":"2016-03","conditions":"Pulmonary Embolism","enrollment":""},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT04536363","phase":"PHASE2","title":"Cri Analog PG1 Effectiveness and Safety in Covid-19","status":"WITHDRAWN","sponsor":"Alonso Vera Torres","startDate":"2020-12-03","conditions":"Covid19","enrollment":""},{"nctId":"NCT02474212","phase":"PHASE4","title":": Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2016-05","conditions":"Venous Thromboembolism, Pulmonary Embolism, Thromboprophylaxis","enrollment":85},{"nctId":"NCT03664180","phase":"PHASE4","title":"Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2019-01-11","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":2989},{"nctId":"NCT02923115","phase":"PHASE1, PHASE2","title":"Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-06-23","conditions":"Pulmonary Embolism, Thrombotic Disease","enrollment":134},{"nctId":"NCT03568838","phase":"PHASE4","title":"Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2018-06-28","conditions":"Myocardial Infarction","enrollment":100},{"nctId":"NCT05334654","phase":"NA","title":"Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients","status":"COMPLETED","sponsor":"University Magna Graecia","startDate":"2022-04-20","conditions":"Acute Respiratory Failure, SARS CoV 2 Infection, Anticoagulants","enrollment":58},{"nctId":"NCT05417997","phase":"PHASE3","title":"Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients","status":"COMPLETED","sponsor":"RAAS Nutritionals, LLC","startDate":"2021-05-29","conditions":"COVID-19 Respiratory Infection, FLU, Cold; Influenza","enrollment":71},{"nctId":"NCT02835534","phase":"PHASE4","title":"The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI","status":"COMPLETED","sponsor":"CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2016-05","conditions":"Acute ST Elevation Myocardial Infarction","enrollment":818},{"nctId":"NCT05304702","phase":"","title":"Lung Injury (Pulmonary Edema) in COVID-19: Treatment With Furosemide and Negative Fluid Balance (NEGBAL)","status":"COMPLETED","sponsor":"Clinica Colon","startDate":"2021-11-28","conditions":"COVID-19","enrollment":120},{"nctId":"NCT04600141","phase":"PHASE3","title":"Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2020-11-10","conditions":"Covid19","enrollment":308},{"nctId":"NCT05172115","phase":"PHASE3","title":"Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-12-22","conditions":"Pulmonary Embolism, Pulmonary Thromboembolisms, Embolism, Pulmonary","enrollment":94},{"nctId":"NCT04372589","phase":"PHASE2, PHASE3","title":"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2020-05-20","conditions":"COVID-19, Pneumonia","enrollment":1200},{"nctId":"NCT04274803","phase":"PHASE4","title":"Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?","status":"WITHDRAWN","sponsor":"Tanta University","startDate":"2020-04-01","conditions":"Antiphospholipid Syndrome in Pregnancy","enrollment":""},{"nctId":"NCT04528888","phase":"PHASE3","title":"Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection","status":"UNKNOWN","sponsor":"Massimo Girardis","startDate":"2020-11-25","conditions":"Covid19, SARS-CoV Infection, Pneumonia, Viral","enrollment":210},{"nctId":"NCT01839487","phase":"PHASE2","title":"PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-05-14","conditions":"Metastatic Pancreatic Cancer","enrollment":279},{"nctId":"NCT03276143","phase":"PHASE2","title":"FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-09-21","conditions":"Knee Arthroplasty, Total","enrollment":813},{"nctId":"NCT02589145","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT04121611","phase":"NA","title":"Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation","status":"UNKNOWN","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-10-14","conditions":"Stroke of Basilar Artery, Optical Coherence Tomography, Antithrombotics","enrollment":25},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT02506985","phase":"PHASE4","title":"XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis","status":"TERMINATED","sponsor":"Susan Smyth","startDate":"2015-07","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":10},{"nctId":"NCT03146858","phase":"PHASE4","title":"Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2017-08-25","conditions":"Primary Percutaneous Coronary Intervention","enrollment":22},{"nctId":"NCT00790335","phase":"PHASE3","title":"Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-11","conditions":"Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome","enrollment":692},{"nctId":"NCT02095509","phase":"PHASE4","title":"Pharmacokinetics of Enoxaparin in Intensive Care Patients","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2014-03","conditions":"Venous Thromboembolism","enrollment":39},{"nctId":"NCT00774748","phase":"NA","title":"Once Weekly Subcutaneous Ports for the Administration of Anticoagulants","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-08","conditions":"Venous Thromboembolism","enrollment":21},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01049633","phase":"","title":"B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT02159287","phase":"PHASE2","title":"Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke","status":"UNKNOWN","sponsor":"Shiraz University of Medical Sciences","startDate":"2014-01","conditions":"Embolic Stroke","enrollment":80},{"nctId":"NCT01863134","phase":"PHASE4","title":"Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up","status":"COMPLETED","sponsor":"Medical University of Silesia","startDate":"2005-01","conditions":"Non ST Elevation Myocardial Infarction","enrollment":140},{"nctId":"NCT01956955","phase":"PHASE4","title":"Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism","status":"UNKNOWN","sponsor":"Ataturk University","startDate":"2011-01","conditions":"This Study Will Provide Data Comparing Safety of LMWH Versus UFH in the Treatment of Acute PE Cases Who Require Thrombolytic Treatment.","enrollment":150},{"nctId":"NCT00916669","phase":"PHASE2","title":"A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2008-07","conditions":"Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00882635","phase":"PHASE3","title":"The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study","status":"COMPLETED","sponsor":"Robert Welsh","startDate":"2008-10","conditions":"Acute Myocardial Infarction","enrollment":44},{"nctId":"NCT00328939","phase":"PHASE3","title":"ARIXTRA Local Study For Registration In China.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05","conditions":"Thromboembolism, Knee Replacement, Hip Replacement","enrollment":240},{"nctId":"NCT00113932","phase":"PHASE2","title":"UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2003-12","conditions":"Multiple Myeloma","enrollment":140},{"nctId":"NCT00790387","phase":"PHASE4","title":"Tirofiban and Enoxaparin in High Risk Coronary Intervention","status":"COMPLETED","sponsor":"The Prince Charles Hospital","startDate":"2004-06","conditions":"Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT00986076","phase":"PHASE4","title":"Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery","status":"COMPLETED","sponsor":"Iladevi Cataract and IOL Research Center","startDate":"2008-03","conditions":"Inflammation","enrollment":23},{"nctId":"NCT00191724","phase":"PHASE2","title":"Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-09","conditions":"Submassive Pulmonary Embolism","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":208,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ARIXTRA infusion"],"phase":"phase_3","status":"active","brandName":"Enoxaparine infusion","genericName":"Enoxaparine infusion","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}